Atherosclerosis News and Research

RSS

Atherosclerosis is the progressive buildup of plaque - the fatty deposits and other cells - in the inner walls of the arteries. The condition is a consequence of elevated cholesterol and for many it's a silent disease, with no visible signs or symptoms. The disease can begin in early adulthood and continues to progress for the rest of a person's life. Despite the serious nature of atherosclerosis, many people do not understand how it develops and progresses.

AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development

With a grant of USD 475,000, the Michael J. Fox Foundation is funding preclinical development of a vaccine against Parkinson's disease by AFFiRiS AG. The vaccine, known as PD01, targets the protein alpha-synuclein and might offer for the first time a possibility for a treatment that can slow or stop the progression of Parkinson's disease.

17 Dec 2010

SBUMC to unveil one-of-a-kind neuroendovascular simulator

Stony Brook University Medical Center will unveil this Friday a one-of-a-kind neuroendovascular simulator that recreates vasculature in the brain, including scenarios of damaged vessels from acute stroke, brain aneurysms, and other cerebrovascular anomalies. Affectionately known in the lab as "Headley".

16 Dec 2010

Gore releases statement in response to safety of GORE HELEX Septal Occluder for PFO closure in cryptogenic stroke patients

W. L. Gore & Associates (Gore) today released the following statement from the Gore REDUCE Clinical Study Principal Investigators on behalf of the Gore REDUCE Clinical Study Steering Committee in response to the recent CLOSURE I results presentation.

14 Dec 2010

Spherix Phase 2 diabetes clinical trial determines minimum D-tagatose dose capable of reducing HbA1c

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 2 diabetes clinical trial, designed to determine the minimum dose of D-tagatose capable of reducing HbA1c, found that the minimum dose capable of affecting HbA1c (7.5 g three-times daily, or TID) was within the range of doses tested

10 Dec 2010

Studies shows that social stress accelerates atherosclerosis development

Studies on genetically engineered mice show that social stress activates the immune system and accelerates the development of atherosclerosis. Commonly used drugs to reduce blood pressure, however, may stop this process. This is the conclusion of a thesis presented at the University of Gothenburg, Sweden.

7 Dec 2010

Appropriate level of Static Magnetic Field exposure for wound patients needs to be considered

The interest in the biological effects of non-ionizing Electro Magnetic Fields (EMFs) and Static Magnetic Fields (SMFs) on the whole organism, as well on cellular systems, has noticeably increased in recent years in consideration of their increased production (from the generation and transmission of electricity, to domestic appliances and industrial equipment, to telecommunications and broadcasting) and the possible health risk for humans.

4 Dec 2010

Exposure to polluted air leads to accumulation of abdominal fat and insulin resistance

Exposure to polluted air early in life led to an accumulation of abdominal fat and insulin resistance in mice even if they ate a normal diet, according to new research.

3 Dec 2010

Spherix announces results of D-tagatose Phase 3 trial for Type 2 diabetes

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced results from its first Phase 3 trial post hoc analysis in which the higher body mass index (BMI) of the U.S. population relative to the Indian population was a likely key contributor to the more positive effects of D-tagatose in the lowering of HbA1c levels in the U.S. population. Initial results were announced on October 7.

2 Dec 2010

Current Opinion in Lipidology journal publishes data on VB-201 for immune-mediated disorders

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of a new concept in the Current Opinion in Lipidology evaluating oxidized phospholipid analogs as potential treatments for chronic inflammatory diseases.

2 Dec 2010

Study identifies new genes responsible for early menarche

University of Minnesota School of Public Health researcher Ellen Demerath, Ph.D., is among an international group of researchers that has identified 30 new genes responsible for determining the age of sexual maturation in women. Many of these genes are also known to influence body fatness, obesity, and energy metabolism. Prior to the multi-institutional study, only four genes had been identified as contributing to the process.

1 Dec 2010

Study finds link between osteoporosis and cardiovascular disease

Norwegian studies indicate that people with osteoporosis have a greater risk of developing cardiovascular disease, and vice versa. Now researchers believe they have found a biological system that may influence both disease processes.

1 Dec 2010

Research could lead to new drug treatment for metabolic diseases

A team of Harvard School of Public Health (HSPH) scientists report finding a molecular "switch" that can "turn off" some cellular processes that are protective against aging and metabolic diseases. While more research is needed, the findings may open doors for new drug treatments to halt or slow development of metabolic diseases like type 2 diabetes or heart disease. The research findings appear in the December 1, 2010 issue of Cell Metabolism.

1 Dec 2010

Vitamin D supplementation may reduce risk of diabetes, heart disease: Research

Researchers from the UC Davis Health System have found that compared with healthy controls, blood levels of vitamin D are significantly reduced in patients in the Sacramento area with metabolic syndrome, a constellation of disease risk factors that affects about one in three U.S. adults and predisposes them to diabetes, heart disease and stroke.

1 Dec 2010

miRagen and t2cure enter licensing agreement for microRNA 92 technology

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, and t2cure, a clinical stage biopharmaceutical company developing progenitor cell-based regenerative therapeutics for cardiac or peripheral vascular diseases, announced today that they have entered into a licensing agreement

30 Nov 2010

Amount of vegetables consumed in childhood correlated to arterial stiffness in adulthood

Eating a lot of fruits and vegetables as a child is associated with healthier arteries as an adult. The amount of vegetables consumed in childhood correlated to the amount of arterial stiffness in adulthood. Children who consistently eat lots of fruits and vegetables lower their risk of having stiff arteries in young adulthood, according to research reported in Circulation: Journal of the American Heart Association.

30 Nov 2010

Heart disease risk factors in childhood predicts likelihood of atherosclerosis as adults

Measuring heart disease risk factors in children at or after age 9 helped predict the likelihood of atherosclerosis in adulthood, according to a study in Circulation: Journal of the American Heart Association.

30 Nov 2010

Resverlogix files new patent for dosing combinations of RVX-208, statin therapeutics

Resverlogix Corp. is pleased to announce today that it has filed additional new patent protection based on novel findings derived from its recently completed ASSERT Phase 2 clinical trial.

30 Nov 2010

People with OSA are prone to develop atherosclerosis: Study

People with obstructive sleep apnea (OSA), a sleep disorder associated with obesity, have more non-calcified or "bad" plaque in their coronary arteries, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

30 Nov 2010

Study confirms difference in coronary artery disease pathways among Caucasians, African Americans

In a study being presented today at the annual meeting of the Radiological Society of North America (RSNA), researchers say they may have an explanation as to why African Americans, despite having lower amounts of coronary artery calcification, are at increased risk for heart attacks and other cardiovascular events compared with Caucasians.

30 Nov 2010

Zalicus to highlight A2A agonist oncology programs at ASH Annual Meeting

Zalicus Inc. announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL on December 4-7, 2010.

29 Nov 2010

Atherosclerosis News and Research

Further Reading

AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development

SBUMC to unveil one-of-a-kind neuroendovascular simulator

Gore releases statement in response to safety of GORE HELEX Septal Occluder for PFO closure in cryptogenic stroke patients

Spherix Phase 2 diabetes clinical trial determines minimum D-tagatose dose capable of reducing HbA1c

Studies shows that social stress accelerates atherosclerosis development

Appropriate level of Static Magnetic Field exposure for wound patients needs to be considered

Exposure to polluted air leads to accumulation of abdominal fat and insulin resistance

Spherix announces results of D-tagatose Phase 3 trial for Type 2 diabetes

Current Opinion in Lipidology journal publishes data on VB-201 for immune-mediated disorders

Study identifies new genes responsible for early menarche

Study finds link between osteoporosis and cardiovascular disease

Research could lead to new drug treatment for metabolic diseases

Vitamin D supplementation may reduce risk of diabetes, heart disease: Research

miRagen and t2cure enter licensing agreement for microRNA 92 technology

Amount of vegetables consumed in childhood correlated to arterial stiffness in adulthood

Heart disease risk factors in childhood predicts likelihood of atherosclerosis as adults

Resverlogix files new patent for dosing combinations of RVX-208, statin therapeutics

People with OSA are prone to develop atherosclerosis: Study

Study confirms difference in coronary artery disease pathways among Caucasians, African Americans

Zalicus to highlight A2A agonist oncology programs at ASH Annual Meeting

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News